Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07261644
PHASE3

A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

This study will evaluate the efficacy and safety of 608 in patients with AS.

Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis (AS)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

500

Start Date

2025-11-07

Completion Date

2027-11-18

Last Updated

2025-12-10

Healthy Volunteers

No

Interventions

DRUG

608 dose

608 subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Locations (1)

Site 01

Beijing, Beijing Municipality, China